BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22381780)

  • 21. Mid-term outcome of positron emission tomography/computed tomography-assisted radiofrequency ablation in primary and secondary liver tumours--a single-centre experience.
    Kuehl H; Stattaus J; Hertel S; Hunold P; Kaiser G; Bockisch A; Forsting M
    Clin Oncol (R Coll Radiol); 2008 Apr; 20(3):234-40. PubMed ID: 18155453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival.
    Mazzaglia PJ; Berber E; Milas M; Siperstein AE
    Surgery; 2007 Jul; 142(1):10-9. PubMed ID: 17629995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Efficacy of radiofrequency ablation to treat advanced hepatocellular carcinoma].
    Wu J; Chen MH; Yang W; Wu W; Yan K
    Zhonghua Gan Zang Bing Za Zhi; 2012 Apr; 20(4):256-60. PubMed ID: 22964144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Usefulness of contrast-enhanced ultrasonography with abdominal virtual ultrasonography in assessing therapeutic response in hepatocellular carcinoma treated with radiofrequency ablation.
    Kisaka Y; Hirooka M; Kumagi T; Uehara T; Hiasa Y; Kumano S; Tanaka H; Michitaka K; Horiike N; Mochizuki T; Onji M
    Liver Int; 2006 Dec; 26(10):1241-7. PubMed ID: 17105590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors.
    Eriksson B; Bergström M; Lilja A; Ahlström H; Långström B; Oberg K
    Acta Oncol; 1993; 32(2):189-96. PubMed ID: 7686763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiofrequency ablation guided by contrast-enhanced ultrasound for hepatic malignancies: preliminary results.
    Dong Y; Wang WP; Gan YH; Huang BJ; Ding H
    Clin Radiol; 2014 Nov; 69(11):1129-35. PubMed ID: 25060936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nuclear imaging of neuroendocrine tumours.
    Sundin A; Garske U; Orlefors H
    Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):69-85. PubMed ID: 17382266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The utility of PET/CT in the management of patients with colorectal liver metastases undergoing laparascopic radiofrequency thermal ablation.
    Sahin DA; Agcaoglu O; Chretien C; Siperstein A; Berber E
    Ann Surg Oncol; 2012 Mar; 19(3):850-5. PubMed ID: 21913009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PET-CT after radiofrequency ablation of colorectal liver metastases: suggestions for timing and image interpretation.
    Nielsen K; van Tilborg AA; Scheffer HJ; Meijerink MR; de Lange-de Klerk ES; Meijer S; Comans EF; van den Tol MP
    Eur J Radiol; 2013 Dec; 82(12):2169-75. PubMed ID: 24021269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contrast-enhanced Ultrasonography for Surveillance of Radiofrequency-ablated Renal Tumors: A Prospective, Radiologist-blinded Pilot Study.
    Allard CB; Coret A; Dason S; Tajzler C; Shayegan B; Matsumoto ED; Kapoor A
    Urology; 2015 Dec; 86(6):1174-8. PubMed ID: 26123518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic response to radiofrequency ablation of neoplastic lesions: FDG PET/CT findings.
    Purandare NC; Rangarajan V; Shah SA; Sharma AR; Kulkarni SS; Kulkarni AV; Dua SG
    Radiographics; 2011; 31(1):201-13. PubMed ID: 21257942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrating contrast-enhanced sonography in the follow-up algorithm of hepatocellular carcinoma treated with radiofrequency ablation: single cancer center experience.
    Catalano O; Izzo F; Vallone P; Sandomenico F; Albino V; Nunziata A; Fusco R; Petrillo A
    Acta Radiol; 2015 Feb; 56(2):133-42. PubMed ID: 24523360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors.
    Del Prete M; Di Sarno A; Modica R; Lassandro F; Giorgio A; Bianco A; Muto M; Gasperi M; Del Prete F; Colao A; Montesarchio V; Faggiano A;
    J Endocrinol Invest; 2017 Dec; 40(12):1373-1380. PubMed ID: 28667452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Other PET tracers for neuroendocrine tumors.
    Koopmans KP; Glaudemans AW
    PET Clin; 2014 Jan; 9(1):57-62. PubMed ID: 25029934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
    Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
    J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of contrast-enhanced ultrasonography after radiofrequency ablation for renal cell carcinoma: is it sufficient for assessment of therapeutic response?
    Kong WT; Zhang WW; Guo HQ; Qiu JL; Tang M; Jiang ZM; Shen Y; Li XG; Zhang SW
    Abdom Imaging; 2011 Jun; 36(3):342-7. PubMed ID: 21107560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive value of pattern classification 24 hours after radiofrequency ablation of liver metastases on CT and positron emission tomography/CT.
    Vandenbroucke F; Vandemeulebroucke J; Ilsen B; Verdries D; Belsack D; Everaert H; Buls N; Ros PR; de Mey J
    J Vasc Interv Radiol; 2014 Aug; 25(8):1240-9. PubMed ID: 24954606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of contrast enhanced ultrasound and contrast enhanced CT or MRI in monitoring percutaneous thermal ablation procedure in patients with hepatocellular carcinoma: a multi-center study in China.
    Lu MD; Yu XL; Li AH; Jiang TA; Chen MH; Zhao BZ; Zhou XD; Wang JR
    Ultrasound Med Biol; 2007 Nov; 33(11):1736-49. PubMed ID: 17629608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiofrequency ablation: a minimally invasive technique with multiple applications.
    Bilchik AJ; Rose DM; Allegra DP; Bostick PJ; Hsueh E; Morton DL
    Cancer J Sci Am; 1999; 5(6):356-61. PubMed ID: 10606477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomography.
    Kuehl H; Rosenbaum-Krumme S; Veit-Haibach P; Stergar H; Forsting M; Bockisch A; Antoch G
    Nucl Med Commun; 2008 Jul; 29(7):599-606. PubMed ID: 18528181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.